Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma [1] (multiple letters)

Cancer

Volumn 88, Issue 9, 2000, Pages 2194-2195

  De Vries, H ^a   Mulder, N H ^a   De Vries, E G E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOXORUBICIN; STREPTOZOCIN;

ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HEART FAILURE; HEPATOMEGALY; HUMAN; LETTER; PANCREAS ISLET CELL CARCINOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, ISLET CELL; CONFIDENCE INTERVALS; DISEASE PROGRESSION; DOXORUBICIN; FOLLOW-UP STUDIES; HUMAN; PALLIATIVE CARE; PANCREATIC NEOPLASMS; QUALITY OF LIFE; REMISSION INDUCTION; STREPTOZOCIN; SURVIVAL RATE;

EID: 0034193137     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2194::AID-CNCR28>3.0.CO;2-R     Document Type: Letter

References (0)